Ex­clu­sive: Shi­no­bi rais­es $51M to take on cell ther­a­py chal­lenges with ex-Wu­gen CEO at helm, Carl June in sup­port

Shi­no­bi Ther­a­peu­tics is try­ing to live up to its moniker, named af­ter the Japan­ese word for nin­ja.

The biotech — a merg­er of two star­tups from Ky­oto, Japan and the Bay Area — aims to cre­ate off-the-shelf cell ther­a­pies that can be re-dosed and de­liv­ered with­out re­quir­ing im­muno­sup­pres­sive drugs, which are some of the at­trib­ut­es that at­tract­ed CAR-T pi­o­neer Carl June to join its sci­en­tif­ic ad­vi­so­ry board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER